Mirum Pharmaceuticals (MIRM) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 221.4% versus a gain of 16.5%. Over five years, MIRM leads with a +402.4% price change compared with +145.3% for ORKA. Mirum Pharmaceuticals is the larger company by market cap ($5.58 billion vs $5.44 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRM | ORKA |
|---|---|---|
| Share price | $86.01 | $82.11 |
| Market cap | $5.58B | $5.44B |
| 1-day change | +5.73% | +6.25% |
| YTD return | +8.89% | +170.90% |
| 1-year return | +16.51% | +221.37% |
| 5-year return | +402.39% | +145.25% |
| EPS (TTM) | $-14.10 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $521.31M | — |
| Revenue growth (YoY) | +54.74% | — |
| Net income (latest FY) | $-23.36M | $-105.43M |
| Operating margin | -4.25% | — |
| Net margin | -4.48% | — |
| 52-week high | $130.00 | $115.52 |
| 52-week low | $63.23 | $24.46 |
| Distance from 52-week high | -33.84% | -28.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.50% | +88.77% |
| Average volume | 695.76K | 902.84K |
| Shares outstanding | 64.93M | 66.21M |
| Employees | 433 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORKA has outperformed MIRM by 204.9 percentage points over the past year.
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
MIRM vs ORKA FAQ
Which is bigger, Mirum Pharmaceuticals or Oruka Therapeutics?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.58B compared with $5.44B for Oruka Therapeutics (ORKA).
Which stock has performed better over the past year, MIRM or ORKA?
ORKA returned +221.37% over the past 12 months, compared with +16.51% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Mirum Pharmaceuticals and Oruka Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Mirum Pharmaceuticals and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Oruka Therapeutics.